(Q37978121)

26 August 2017

Vaccination against infection in patients with multiple sclerosis (English)

1 reference

26 August 2017

0 references

3

Hans-Peter Hartung

1 reference

26 August 2017

4

Hartmut Hengel

1 reference

26 August 2017

Micha Loebermann

1

1 reference

26 August 2017

Alexander Winkelmann

series ordinal

2

1 reference

26 August 2017

Emil C Reisinger

series ordinal

5

1 reference

26 August 2017

Uwe K Zettl

series ordinal

6

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

26 August 2017

Nature Reviews Neurology

1 reference

26 August 2017

8

1 reference

26 August 2017

3

1 reference

26 August 2017

143-151

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2012.8

26 August 2017

0 references

cites work

Environmental risk factors for multiple sclerosis. Part I: The role of infection

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Environmental factors and their timing in adult-onset multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

The risk of relapses in multiple sclerosis during systemic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Prospective study on the relationship between infections and multiple sclerosis exacerbations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Could autoimmunity be induced by vaccination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Immunizations and risk of multiple sclerosis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Immunization and MS: a summary of published evidence and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Vaccinations and Risk of Central Nervous System Demyelinating Diseases in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Tetanus vaccination and risk of multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Influenza vaccination in MS: absence of T-cell response against white matter proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Influenza vaccination in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Tick-borne encephalitis virus - a review of an emerging zoonosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

The neglected arboviral infections in mainland China

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Demyelinating disease and hepatitis B vaccination: is there a link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Hepatitis B vaccination and the risk of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

CNS demyelination and quadrivalent HPV vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Rotavirus vaccines: viral shedding and risk of transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

The varicella zoster virus: a pilot trial of a potential therapeutic agent in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Tuberculosis vaccines in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Influenza vaccination in kidney transplant recipients: cellular and humoral immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Protective role of beta interferon in host defense against influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

The 5-year direct medical cost of neonatal and childhood stroke in a population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Managing the risks of immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Prognostic factors in multiple sclerosis: role of intercurrent infections and vaccinations against influenza and hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Swine Influenza Virus Vaccination in Patients with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Neurologic disorders after measles-mumps-rubella vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Hepatitis B vaccination and multiple sclerosis: a data mining perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Aktuelle Empfehlungen zu Impfungen bei Multipler Sklerose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Immunology: Prevention of infections in patients with autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Safety of tetanus vaccination in relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Serial magnetic resonance imaging studies with paramagnetic contrast medium: assessment of disease activity in patients with multiple sclerosis before and after influenza vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Seasonal and H1N1v influenza vaccines in MS: safety and compliance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

INFECTION AND IMMUNIZATION IN MULTIPLE SCLEROSIS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Fingolimod treatment for multiple sclerosis patients What do we do with varicella?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Immunization in the adult immunocompromised host

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

[Current opinion 2004: The relationship between multiple sclerosis and hepatitis B vaccination in adults]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Multiple sclerosis and vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.8

Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives.

31 March 2020

1 reference

12 December 2020

Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993

1 reference

12 December 2020

Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products

1 reference

12 December 2020

Neuromyelitis optica following human papillomavirus vaccination.

1 reference

12 December 2020

Multiple sclerosis after hepatitis B vaccination in a 16-year-old patient

1 reference

12 December 2020

Specific antibody response after influenza immunization in systemic lupus erythematosus.

1 reference

12 December 2020

Managing multiple sclerosis in primary care: are we forgetting something?

1 reference

12 December 2020

1 reference

12 December 2020

A severe episode in a patient with recurrent disseminated acute encephalitis due to vaccination against hepatitis B. For or against vaccination?

1 reference

12 December 2020

Causality assessment of adverse events following immunization

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2012.8

1 reference

26 August 2017

1 reference